Senior Vice President, Research
CSL Limited


Dr Andrew Nash PhD

andrew-nash_research-australia

Senior Vice President, Research
CSL Limited

Dr Andrew Nash is the Senior Vice President for Research at CSL Limited, as well as an Honorary Associate Professor at the Bio21 Institute at the University of Melbourne. He has extensive experience in the pharmaceutical / biotechnology sector, including at the CEO level. Dr Nash completed his PhD in immunology at The University of Melbourne in 1988 and, after moving to the Centre for Animal Biotechnology in the Faculty of Veterinary Science, developed and led a research group focused on basic and applied aspects of cytokine biology. In 1996 he joined the ASX listed biotechnology company Zenyth Therapeutics (then Amrad Corporation) as a senior scientist and subsequently held a number of positions including Director of Biologicals Research and Chief Scientific Officer.

In July of 2005 he was appointed Chief Executive Officer of Zenyth, a position which he held up until the acquisition of Zenyth by CSL Limited in November 2006. Following the acquisition he was appointed as CSL’s Senior Vice President, Research and currently leads a large team focused on the discovery and development of new recombinant antibody / protein-based medicines to treat serious human disease.

Dr Nash is an honorary Associate Professor at the University of Melbourne and is a graduate of the Australian Institute of Company Directors. Dr Nash has published extensively in peer-reviewed publications and has inventorship on numerous patent filings.